There are 41 papers on colorectal neoplasm in aging research: 3 trials and 26 observational studies in people, 1 in animals, 9 reviews.
3 new papers in 30 daysSee all 49 papers on colorectal neoplasm
“In CHARLS, fully adjusted models showed strong associations for TyG (OR = 3.98, 95% CI: 2.66–5.94)”
- Human trial3
- Humans26
- Animals1
- In silico2
Upstream
425-hydroxyvitamin D
no changein humans1
1 study
25-hydroxyvitamin D
no changein humans1
25-hydroxyvitamin D was not clearly linked with colorectal neoplasm in humans (Lynch syndrome carriers).
HumansLynch syndrome carriers
LEP
no changein humans1
1 study
LEP
no changein humans1
LEP was not clearly linked with colorectal neoplasm in humans (fully adjusted model) (IRR: 0.95).
Humansfully adjusted modeln = 602
Metabolic syndrome
no changein humans1
1 study
Metabolic syndrome
no changein humans1
Metabolic syndrome was not clearly linked with colorectal neoplasm in humans (fully adjusted model) (IRR: 1.06; 95% CI, 0.83-1.36).
Humansfully adjusted modeln = 4,891
Obstructive sleep apnea
no changein humans1
1 study
Obstructive sleep apnea
no changein humans1
Obstructive sleep apnea was not clearly linked with colorectal neoplasm in humans.
Humansn = 335
Associations
17Age
upin humans2OR 1.061
2 studies
Age
upin humans2OR 1.061
Age is associated with colorectal neoplasm in humans (Population at high risk for colorectal tumors) (OR 1.061, 95% CI 1.038–1.083).
HumansPopulation at high risk for colorectal tumors
Age is linked with a higher risk of colorectal neoplasm in humans (fully adjusted model) (IRR: 1.73 per decade; 95% CI, 1.53-1.95).
Humansfully adjusted modeln = 4,891
IMCS LR model
upin humans1
1 study
IMCS LR model
upin humans1
IMCS LR model predicts colorectal neoplasm in humans (Validation set) (Validation-set AUC 0.690, 95% CI 0.644–0.736).
HumansValidation set
IMCS XGBoost model
upin humans1
1 study
IMCS XGBoost model
upin humans1
IMCS XGBoost model predicts colorectal neoplasm in humans (Training set) (Training-set AUC 0.817, 95% CI 0.794–0.841).
HumansTraining set
PSQI score
upin humans1OR 1.512
1 study
PSQI score
upin humans1OR 1.512
PSQI score is associated with colorectal neoplasm in humans (Population at high risk for colorectal tumors) (OR 1.512, 95% CI 1.003–2.279).
HumansPopulation at high risk for colorectal tumors
TyG-related indices
mixedin humans1
1 study
TyG-related indices
mixedin humans1
TyG-related indices predict colorectal neoplasm in humans (ROC analyses in CHARLS and NHANES) (AUCs 0.767–0.786 in CHARLS; 0.570–0.587 in NHANES).
HumansROC analyses in CHARLS and NHANES
TyG-WWI
upin humans1OR 1.08
1 study
TyG-WWI
upin humans1OR 1.08
TyG-WWI is associated with colorectal neoplasm in humans (CHARLS; fully adjusted logistic regression) (OR 1.08, 95% CI 1.06–1.11).
HumansCHARLS; fully adjusted logistic regressionn = 9,293
TyG-HGB
upin humans1OR 1.28
1 study
TyG-HGB
upin humans1OR 1.28
TyG-HGB is associated with colorectal neoplasm in humans (CHARLS; fully adjusted logistic regression) (OR 1.28, 95% CI 1.20–1.36).
HumansCHARLS; fully adjusted logistic regressionn = 9,293
TyG-CI
upin humans1OR 2
1 study
TyG-CI
upin humans1OR 2
TyG-CI is associated with colorectal neoplasm in humans (CHARLS; fully adjusted logistic regression) (OR 2.00, 95% CI 1.60–2.50).
HumansCHARLS; fully adjusted logistic regressionn = 9,293
Triglyceride-glucose index
upin humans1OR 3.98
1 study
Triglyceride-glucose index
upin humans1OR 3.98
Triglyceride-glucose index is associated with colorectal neoplasm in humans (CHARLS; fully adjusted logistic regression) (OR 3.98, 95% CI 2.66–5.94).
HumansCHARLS; fully adjusted logistic regressionn = 9,293
Multitarget stool DNA
upin humans1
1 study
Multitarget stool DNA
upin humans1
Multitarget stool DNA predicts colorectal neoplasm in samples completing both tests (100.0% - 43.0% and 53.3% - 27.2%).
Reviewin samples completing both tests
All 17Fewer
Trial sponsors
Company3 trialsPhase 4409 people
Company1 trialPhase 4150 people
Company12 trialsPhase 32,637 people
Company6 trialsPhase 3487 people
Company5 trialsPhase 32,589 people
Company5 trialsPhase 3860 people
Company4 trialsPhase 31,711 people
Janssen Research & Development
Company3 trialsPhase 31,960 people
Funding
5 grants since 2018National Cancer Institute$3.3M
PROSPECT: Pathways, Risk factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
National Cancer InstituteBroad Institute$316K2024–2026
PROSPECT: Pathways, Risk factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
National Cancer InstituteHarvard University$614K2024–2026
MGH- PROSPECT: Pathways, Risk factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
National Cancer InstituteMassachusetts General Hospital$681K2024–2026
PROSPECT: Pathways, Risk factors, and mOleculeS to Prevent Early-onset Colorectal Tumors
National Cancer InstituteKing's College London$333K2024–2026
National Cancer InstituteSloan-kettering Inst Can Research$85.2K2018–2020